Entera Bio Ltd (ENTX)

$1.11 -0.08 (-6.72%)
Market Cap 61.45M
Revenue (ttm) 180,000.00
Net Income (ttm) -9.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,300.00%
Debt to Equity Ratio 0.00
Volume 152,100
Avg Vol 179,144
Day's Range N/A - N/A
Shares Out 45.86M
Stochastic %K 6%
Beta 1.83
Analysts Sell
Price Target $10.00

Company Profile

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis;...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 532 7151
Address:
Kiryat Hadassah Minrav Building, Fifth Floor, Jerusalem, Israel
newlifegal
newlifegal Mar. 17 at 3:38 PM
$ACXP take your profit and move to the next thing $ENTX
0 · Reply
newlifegal
newlifegal Mar. 17 at 3:34 PM
$LNAI take your profits and go to $ENTX
0 · Reply
newlifegal
newlifegal Mar. 17 at 3:33 PM
$ENTX for profits now and tomorrow
0 · Reply
newlifegal
newlifegal Mar. 17 at 3:32 PM
$BIAF take your profits and move to $ENTX
0 · Reply
Elegant_Confusion
Elegant_Confusion Mar. 12 at 6:27 AM
$ENTX because there have been multiple insider buys in early 2026 (see SEC Form 4 filings), including several in just the last few days.
1 · Reply
WallStWireAds
WallStWireAds Mar. 11 at 12:44 PM
$ENTX Form 4 for newly appointed ex-pfizer chairman Geno Germano shows another insider purchase, available from IR website here: https://investors.enterabio.com/static-files/aa40f3f8-3023-4cd7-a2fe-37d4bd16ed08
0 · Reply
TheBlackBerrry
TheBlackBerrry Mar. 9 at 2:09 PM
$REBN STARTING TO MOVE DONT MISS IT $ENTX $BURU $AZI $NVVE
0 · Reply
rombrento
rombrento Mar. 9 at 6:09 AM
$ENTX
0 · Reply
Jennx6
Jennx6 Mar. 5 at 8:37 PM
$ENTX Seriously...why down? I'll grab a few more, I guess.
0 · Reply
WallStWireAds
WallStWireAds Mar. 5 at 2:40 PM
$ENTX https://www.benzinga.com/content/51064997/entera-bio-moves-toward-phase-3-with-oral-therapy-that-could-transform-osteoporosis-treatment-nasdaq
0 · Reply
Latest News on ENTX
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Mar 4, 2026, 8:30 AM EST - 17 days ago

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Entera Bio Announces Open Market Purchases of Company Stock by Board Members

Feb 11, 2026, 9:00 AM EST - 5 weeks ago

Entera Bio Announces Open Market Purchases of Company Stock by Board Members

Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones

Feb 9, 2026, 8:50 AM EST - 5 weeks ago

Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones

Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

Dec 23, 2025, 8:30 AM EST - 3 months ago

Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

Dec 22, 2025, 8:30 AM EST - 3 months ago

Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 4 months ago

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

Oct 23, 2025, 8:50 AM EDT - 5 months ago

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

Oct 16, 2025, 8:45 AM EDT - 5 months ago

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Aug 8, 2025, 4:05 PM EDT - 8 months ago

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

Jul 28, 2025, 7:30 AM EDT - 8 months ago

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

May 9, 2025, 4:05 PM EDT - 11 months ago

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

Mar 28, 2025, 4:05 PM EDT - 1 year ago

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Mar 17, 2025, 8:00 AM EDT - 1 year ago

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Events

Feb 24, 2025, 8:30 AM EST - 1 year ago

Entera Bio to Participate in Upcoming Events

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 27, 2025, 8:00 AM EST - 1 year ago

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Nov 8, 2024, 4:05 PM EST - 1 year ago

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Aug 9, 2024, 4:05 PM EDT - 1 year ago

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

May 15, 2024, 8:00 AM EDT - 2 years ago

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

May 10, 2024, 4:10 PM EDT - 2 years ago

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Mar 26, 2024, 8:30 AM EDT - 2 years ago

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Mar 20, 2024, 8:00 AM EDT - 2 years ago

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Mar 8, 2024, 4:05 PM EST - 2 years ago

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 4, 2024, 8:30 AM EST - 2 years ago

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 30, 2024, 8:30 AM EST - 2 years ago

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Jan 3, 2024, 8:00 AM EST - 2 years ago

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Dec 26, 2023, 8:00 AM EST - 2 years ago

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Nov 29, 2023, 8:30 AM EST - 2 years ago

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Nov 14, 2023, 7:30 AM EST - 2 years ago

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Nov 9, 2023, 2:30 PM EST - 2 years ago

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Sep 12, 2023, 8:30 AM EDT - 2 years ago

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Entera Bio to Participate in Upcoming Investor Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Entera Bio to Participate in Upcoming Investor Conferences

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Aug 16, 2023, 8:30 AM EDT - 2 years ago

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

Jun 7, 2023, 7:30 AM EDT - 3 years ago

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

May 5, 2023, 4:05 PM EDT - 3 years ago

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

May 3, 2023, 9:34 AM EDT - 3 years ago

Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board

Apr 26, 2023, 8:30 AM EDT - 3 years ago

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

Apr 3, 2023, 7:00 AM EDT - 3 years ago

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

Mar 31, 2023, 4:00 PM EDT - 3 years ago

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

Entera Bio Regains Compliance with Nasdaq Listing Requirements

Mar 23, 2023, 9:27 AM EDT - 3 years ago

Entera Bio Regains Compliance with Nasdaq Listing Requirements

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Feb 15, 2023, 10:00 AM EST - 3 years ago

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

Feb 13, 2023, 9:00 AM EST - 3 years ago

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

Nov 10, 2022, 4:15 PM EST - 3 years ago

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

Oct 6, 2022, 7:00 AM EDT - 3 years ago

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET

Sep 21, 2022, 8:30 AM EDT - 3 years ago

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET

newlifegal
newlifegal Mar. 17 at 3:38 PM
$ACXP take your profit and move to the next thing $ENTX
0 · Reply
newlifegal
newlifegal Mar. 17 at 3:34 PM
$LNAI take your profits and go to $ENTX
0 · Reply
newlifegal
newlifegal Mar. 17 at 3:33 PM
$ENTX for profits now and tomorrow
0 · Reply
newlifegal
newlifegal Mar. 17 at 3:32 PM
$BIAF take your profits and move to $ENTX
0 · Reply
Elegant_Confusion
Elegant_Confusion Mar. 12 at 6:27 AM
$ENTX because there have been multiple insider buys in early 2026 (see SEC Form 4 filings), including several in just the last few days.
1 · Reply
WallStWireAds
WallStWireAds Mar. 11 at 12:44 PM
$ENTX Form 4 for newly appointed ex-pfizer chairman Geno Germano shows another insider purchase, available from IR website here: https://investors.enterabio.com/static-files/aa40f3f8-3023-4cd7-a2fe-37d4bd16ed08
0 · Reply
TheBlackBerrry
TheBlackBerrry Mar. 9 at 2:09 PM
$REBN STARTING TO MOVE DONT MISS IT $ENTX $BURU $AZI $NVVE
0 · Reply
rombrento
rombrento Mar. 9 at 6:09 AM
$ENTX
0 · Reply
Jennx6
Jennx6 Mar. 5 at 8:37 PM
$ENTX Seriously...why down? I'll grab a few more, I guess.
0 · Reply
WallStWireAds
WallStWireAds Mar. 5 at 2:40 PM
$ENTX https://www.benzinga.com/content/51064997/entera-bio-moves-toward-phase-3-with-oral-therapy-that-could-transform-osteoporosis-treatment-nasdaq
0 · Reply
WallStWireAds
WallStWireAds Mar. 4 at 1:32 PM
$ENTX https://caplynx.io/BYEoxP0
0 · Reply
WallStWireAds
WallStWireAds Feb. 26 at 1:02 PM
$ENTX https://caplynx.io/ALVNwRp
0 · Reply
WallStWireAds
WallStWireAds Feb. 25 at 2:07 PM
$ENTX https://alphacatalyst.beehiiv.com/p/an-executive-from-pfizer-just-joined-this-microcap-followed-by-an-insider-buying-spree-nasdaq-entx
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 24 at 9:03 PM
$ENTX Current Stock Price: $1.58 Contracts to trade: $2.5 ENTX Mar 20 2026 Call Entry: $0.10 Exit: $0.14 ROI: 39% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 9:23 PM
$ENTX RSI: 54.03, MACD: -0.0554 Vol: 0.15, MA20: 1.41, MA50: 1.64 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TapeHunter
TapeHunter Feb. 18 at 10:12 AM
$ENTX Oncology biotech with platform optionality; dilution risk present.
0 · Reply
SocioCobb
SocioCobb Feb. 17 at 2:33 PM
$ENTX
0 · Reply
SweepAlex
SweepAlex Feb. 17 at 9:24 AM
$ENTX Pre-revenue biotech; early-stage
0 · Reply
mikesterz7
mikesterz7 Feb. 12 at 2:51 AM
$ENTX According to a filing with the Securities and Exchange Commission, Germano purchased 20,000 shares at $1.49 a piece.
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 11 at 9:06 PM
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead $ENTX https://stocktwits.com/news/equity/markets/entx-rallies-as-insiders-buy-company-shares/cZb6pAeR4Ah
0 · Reply